116 related articles for article (PubMed ID: 18781300)
1. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
Saif MW; Peccerillo J; Potter V
Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
[TBL] [Abstract][Full Text] [Related]
2. Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions.
Lofy M; Jung L; Dow-Hillgartner E
J Oncol Pharm Pract; 2024 Mar; 30(2):412-416. PubMed ID: 37936371
[TBL] [Abstract][Full Text] [Related]
3. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
Martinelli E; De Palma R; Orditura M; De Vita F; Ciardiello F
Clin Exp Immunol; 2009 Oct; 158(1):1-9. PubMed ID: 19737224
[TBL] [Abstract][Full Text] [Related]
4. Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series.
Okunaka M; Kotani D; Mishima S; Nakamura M; Kawazoe A; Bando H; Yoshino T; Shitara K
Integr Cancer Ther; 2024; 23():15347354231225962. PubMed ID: 38240253
[TBL] [Abstract][Full Text] [Related]
5. A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer.
Ishiguro M; Watanabe T; Yamaguchi K; Satoh T; Ito H; Seriu T; Sakata Y; Sugihara K
Jpn J Clin Oncol; 2012 Apr; 42(4):287-94. PubMed ID: 22327124
[TBL] [Abstract][Full Text] [Related]
6. Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations.
Carpanese D; Rossi V; Di Paolo V; Quintieri L; Penna A; Zuccolotto G; Sebellin J; Saran C; Pipitone F; Miolo G; De Diana E; Realdon N; Rigamonti N; Di Sarra F; Coppola M; Rosato A
Int J Pharm; 2024 Jan; 649():123643. PubMed ID: 38040395
[TBL] [Abstract][Full Text] [Related]
7. Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review.
Leporini C; Saullo F; Filippelli G; Sorrentino A; Lucia M; Perri G; Gattuta GL; Infusino S; Toscano R; Dima G; Olivito V; Paletta L; Bottoni U; De Sarro G
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S78-85. PubMed ID: 24347989
[TBL] [Abstract][Full Text] [Related]
8. A rare but severe pulmonary side effect of cetuximab in two patients.
Achermann Y; Frauenfelder T; Obrist S; Zaugg K; Corti N; Günthard HF
BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22843749
[TBL] [Abstract][Full Text] [Related]
9. Hypersensitivity to oxaliplatin: clinical features and risk factors.
Parel M; Ranchon F; Nosbaum A; You B; Vantard N; Schwiertz V; Gourc C; Gauthier N; Guedat MG; He S; Kiouris E; Alloux C; Vial T; Trillet-Lenoir V; Freyer G; Berard F; Rioufol C
BMC Pharmacol Toxicol; 2014 Jan; 15():1. PubMed ID: 24417770
[TBL] [Abstract][Full Text] [Related]
10. Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review.
Hoag JB; Azizi A; Doherty TJ; Lu J; Willis RE; Lund ME
J Exp Clin Cancer Res; 2009 Aug; 28(1):113. PubMed ID: 19682368
[TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity Reactions to Monoclonal Antibodies in Children.
Mori F; Saretta F; Bianchi A; Crisafulli G; Caimmi S; Liotti L; Bottau P; Franceschini F; Paglialunga C; Ricci G; Santoro A; Caffarelli C
Medicina (Kaunas); 2020 May; 56(5):. PubMed ID: 32408641
[TBL] [Abstract][Full Text] [Related]
12. Panitumumab-Induced Periorbital Dermatitis: A Case Report.
Pongbangpho N; Chanprapaph K; Iamsumang W
Clin Cosmet Investig Dermatol; 2024; 17():763-767. PubMed ID: 38586180
[TBL] [Abstract][Full Text] [Related]
13. Substitution with Low-Osmolar Iodinated Contrast Agent to Minimize Recurrent Immediate Hypersensitivity Reaction.
Kim S; Jeon KN; Jung JW; Park HK; Lee W; Lee J; Kang HR
Radiology; 2023 Oct; 309(1):e222467. PubMed ID: 37906013
[TBL] [Abstract][Full Text] [Related]
14. The role of IgE specific for galactose-α-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis.
Lungulescu CV; Ungureanu BS; Turcu-Stiolica A; Ghimpau V; Artene SA; Cazacu IM; Grecu AF; Dinescu VC; Croitoru A; Volovat SR
Sci Rep; 2020 Dec; 10(1):21355. PubMed ID: 33288791
[TBL] [Abstract][Full Text] [Related]
15. Cancer therapy related cardiac dysfunction as a result of Panitumumab.
Senechal I; Vogiatzakis N; Andres MS; Tong J; Ramalingam S; Rosen SD; Lyon AR; Nazir MS
Cardiooncology; 2024 Apr; 10(1):23. PubMed ID: 38605419
[TBL] [Abstract][Full Text] [Related]
16. A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers.
Urban C; Anadkat MJ
J Gastrointest Oncol; 2013 Sep; 4(3):319-27. PubMed ID: 23997943
[TBL] [Abstract][Full Text] [Related]
17. The future of tumour-specific fluorescence-guided surgery for pancreatic cancer.
Lwin TM; Hoffman RM; Bouvet M
Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):715-717. PubMed ID: 32416765
[No Abstract] [Full Text] [Related]
18. Trichomegaly Due to Panitumumab.
Taboada Paz L; Vicente Basanta E; Monteagudo Sánchez B
JAMA Dermatol; 2024 Apr; ():. PubMed ID: 38656343
[TBL] [Abstract][Full Text] [Related]
19. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
20. Alpha-Gal-containing biologics and anaphylaxis.
Chinuki Y; Morita E
Allergol Int; 2019 Jul; 68(3):296-300. PubMed ID: 31053502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
